Tag: merger
-
Merger to Form Programmable Nano-Medicines Company
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties.
-
Infographic – Q2 Tech Merger Values Up, Deals Down
The value of mergers and acquisitions in the global technology sector rose for the first time in over a year in the second quarter of 2023, while M&A deal counts dropped somewhat.
-
Regeneron Acquires Hearing Loss Biotech in $213M Deal
Regeneron Pharmaceuticals, a maker of synthetic biologic treatments, is acquiring Decibel Therapeutics, developer of gene therapies to treat hearing loss and balance disorders.
-
Computational Drug Discovery Company Acquires A.I. Businesses
Two companies using artificial intelligence to advance biotechnology and design new therapies are merging with a computational-engineering drug discovery enterprise.
-
Cell Biology Tools Companies Merge in $57.8M Deal
Two providers of technologies for cellular analysis are merging to form a new company focusing on cell biology research tools, in a sign of continued industry consolidation.
-
Mental Health VR Companies Merge, Raise $13M
Two developers of virtual reality therapy technology for mental health disorders are combining their operations, and raising $13 million in venture funds.
-
Gut-Brain Meds Developer Going Public in Merger
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, in a deal expected to…
-
Immune Disease Biotech Acquired in $405M Deal
A biotechnology developer of treatments for autoimmune disorders with checkpoint receptor proteins is acquired by drug maker Gilead Sciences.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Diabetes Cell Therapy Biotech Acquired in $320M Deal
A developer of therapies derived from stem cells to replace malfunctioning islet cells in people with type 1 diabetes was acquired by Vertex Pharmaceuticals.